Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtlantic Lithium Regulatory News (ALL)

Share Price Information for Atlantic Lithium (ALL)

Share Price is delayed by 15 minutes
Get Live Data
16.35    -0.10 (-0.61%)
Bid:
16.30
Ask:
16.45
Spread: 0.15 (0.92%)
Market Cap: £131.05m
ALL Live PriceLast checked at - London Stock Exchange

Intraday Atlantic Lithium Share Chart

Full Year Trading Update

26 Jun 2012 07:00

RNS Number : 1056G
Allocate Software PLC
26 June 2012
Β 

ο»Ώ

ALLOCATE SOFTWARE PLC

("Allocate" or "the Company")

Β 

Β 

Full Year Trading Update

Β 

Allocate Software (AIM: ALL), the leading provider of workforce and compliance optimisation solutions, announces an update on trading for its financial year ended 31 May 2012. The Company's final results will be announced in the week commencing 30 July 2012.

Β 

Highlights

Β 

Β§ Strong financial performance in the year with results expected to be in line with market expectations.

Β 

Β§ Healthcare had another successful year securing new customers across the NHS, in the UK private healthcare sector and overseas.

Β 

Β§ Completed two acquisitions in the financial year: Zircadian in the UK and RosterOn in Australia. Both performed in line with expectations and the cross-sell of different products into the customer base is beginning to yield encouraging results.

Β 

Β§ Defence had a record year, with major contract wins worldwide including the multi million pound agreement with the Australian Defence Forces.

Β 

Healthcare

Β 

Because of the drive in the NHS for efficiency and cost savings, market appetite for the Allocate application suite with its proven ROI remained strong, with new customers, new products, licence renewals and extensions. HealthRoster, our e-rostering product, retained its strong competitive position and was selected in the majority of all competitive tenders in the UK during the fiscal year.

Β 

The release of v10, the fully web-based version of HealthRoster with multi-language capability, positions this product well for further internationalisation. Our Swedish business, Time Care, has again performed well and met expectations as it has now done every year since acquisition. HealthRoster will be available in Swedish as the first internationalisation of HealthRoster in the coming months.

Β 

Leveraging acquisitions - the integration of HealthRoster and the Zircadian products with the rest of the Allocate suite of products provides customers with an end to end solution from planning to scheduling of the medical workforce. In addition, the integration of HealthRoster and the RosterOn product has created a bespoke leading employment awards interpretation engine for the Australian market. The broadening of our product range is creating significant cross-sell opportunities, in line with our strategy.

Β 

Defence

Β 

The Defence business achieved substantial growth and continued diversifying into other geographic regions, generating significant business from overseas. Highlights include:

Β 

Β§ Securing a multi-million pound licence contract with the Australian Defence Department extending the use of Defence Suite across the Army, Navy and civilians under military control.

Β§ Substantial additional Consultancy Services contract extension wins with the Royal Australian Navy, as part of their New Generation Navy programme.

Β§ Two new Consultancy Services contract wins in NATO within their Force Operations Group, and Special Forces HQ.

Β§ Extension of the UK Army Support contract to 2014

Β 

Maritime

Β 

Β§ Secured a new licence agreement with McDermott Inc, a major US offshore engineering company, the third in this sector

Β§ Completed a major Maritime Suite implementation to support SubSea7's global Offshore Oil Services operations

Β 

Β 

Ian Bowles, Chief Executive Officer of Allocate commented: "Despite the global economic environment and the macro economics of UK government spending we have executed well in our industry sectors and I am delighted with the performance of Allocate this year, particularly in the second half.

Β 

"2012 was our sixth consecutive year of record revenue. This consistency of execution, I believe, demonstrates a balance across our business, both in terms of vertical markets and geographical focus, which speaks well to our plans for significant growth over the next three to five years. I am very pleased with this year's performance and look forward to Allocate's continued success in the next financial year".

Β 

Β 

Enquiries:

Allocate Software plc

Ian Bowles - Chief Executive Officer

Chris Gale - Chief Financial Officer

Martin Jeffries - Marketing Director

Β 

Tel: +44 (0) 20 7355 5555

Numis Securities

Nominated adviser - Michael Meade / Simon Willis/ Richard Thomas

Corporate Broking - James Black

Β 

Tel: +44 (0) 20 7260 1000

Gable Communications

Justine James / John Bick

Β 

Tel: +44 (0) 20 7193 7463

M: +44 (0) 7525 324431

Β 

About Allocate Software plc

Allocate Software plc is the leading workforce optimisation software applications provider for world-wide organisations with large, multi-skilled workforces. With a blue chip client base spanning the public and private sector, its key vertical markets include: Healthcare and Defence.

Β 

At the core of the business is Allocate's workforce optimisation software, which organisations use to deploy the right people with the right skills, to the right place at the right time. Headquartered in London, Allocate provides services and support to its increasing international customer base through regional offices in the UK, Sweden, USA, Australia and Malaysia.

Β 

Allocate is quoted on the London Stock Exchange (AIM: ALL). For further information please visit www.allocatesoftware.com.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTUVRNRUOANUAR
Date   Source Headline
30th Mar 20237:00 amRNSConference Attendance
24th Mar 20237:00 amRNSCorporate Update - Director/PDMR Shareholding
22nd Mar 20237:00 amRNSDefinitive Feasibility Study Project Update
20th Mar 20237:00 amRNS2023 Exploration and Resource Programmes Update
20th Mar 20237:00 amRNSDirector/PDMR Shareholding
17th Mar 20237:05 amRNSInvestor Presentation
17th Mar 20237:00 amRNSHolding(s) in Company
15th Mar 20237:00 amRNSCorporate Update and Half-year Financial Report
9th Mar 20238:15 amRNSRestoration - Atlantic Lithium Limited
9th Mar 20238:00 amRNSResponse to Online Report & Restoration of Trading
8th Mar 20234:15 pmRNSSuspension - Atlantic Lithium Limited
1st Mar 20238:00 amRNSResults of Extraordinary General Meeting
21st Feb 20237:00 amRNSCommunications Update - Conference Attendance
17th Feb 20237:00 amRNSExpression of Interest - Investment by MIIF
13th Feb 20239:00 amRNSRicca Resources - Pre-IPO Placement
3rd Feb 20238:00 amRNSCorporate Communication Update Mining Indaba 2023
1st Feb 20237:00 amRNSEwoyaa Mineral Resource increases to 35.3Mt
31st Jan 20237:00 amRNSNotice of Extraordinary General Meeting
30th Jan 20237:00 amRNSQuarterly Activities and Cash Flow Report Dec 2022
20th Jan 20237:00 amRNSCorporate Update – 2023 OTCQX Best 50 - ALLIF
12th Jan 20237:00 amRNSFinal Assay Results and New High-Grade pegmatites
30th Dec 20228:00 amRNSCorporate Update Change of terms for Share Options
13th Dec 20227:00 amRNSPrimero awarded FEED Contract for Ewoyaa Lithium
5th Dec 20227:00 amRNSCommunication Update - LSE Investor Webinar
30th Nov 20227:15 amRNSCorporate Update - Result of 2022 AGM
29th Nov 20227:00 amRNSHigh-Grade Drill Results - Highest Grade to Date
28th Nov 20227:00 amRNSAppointment of Alternate Director
28th Nov 20227:00 amRNSCommencement of COO and Issue of Options
22nd Nov 20227:00 amRNSTR1 Notification of Major Holdings
16th Nov 20227:00 amRNSCorporate Update - Mines & Money London 2022
9th Nov 20227:38 amRNSSignificant Potential for Resource Upgrades
2nd Nov 20227:00 amRNSHighest Reported Grade to Date of 4.52% Li2O
31st Oct 20227:00 amRNSNotice of AGM
27th Oct 20227:10 amRNSAppointment of Chief Operating Officer
27th Oct 20227:05 amRNSQuarterly Activities and Cash Flow Report
27th Oct 20227:00 amRNSInvestor Presentation for Webinar
21st Oct 20227:00 amRNSCorporate Communication Update - Investor Webinar
20th Oct 20227:00 amRNSOngoing High-Grade Lithium Intersections at Ewoyaa
13th Oct 20227:00 amRNSMining Licence Application Lodged for Ewoyaa
12th Oct 20227:00 amRNSCorporate Update - Conference Attendance
30th Sep 20227:30 amRNSCorporate Update – 2022 Annual Financial Report
28th Sep 202210:00 amRNSPiedmont Partner Atlantic Lithium Completes PFS
26th Sep 202210:00 amRNSASX Listing – Commencement of Trading
22nd Sep 20227:00 amRNSRobust Ewoyaa Pre-Feasibility Study
21st Sep 20227:01 amRNSASX Listing – Admission to Official List
19th Sep 20227:00 amRNSCorporate Update - Issue of Equity / PCA Dealings
16th Sep 20222:00 pmRNSTR1 Notification of Significant Shareholding
8th Sep 202210:00 amRNSCorporate Update Dual Listing – Close of ASX Offer
30th Aug 202212:00 pmRNSCorporate Communication Update - Africa Down Under
30th Aug 202210:00 amRNSLodgement of Dual Listing Replacement Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.